Last reviewed · How we verify
Rabies
Rabies vaccine, marketed by Novartis Vaccines, holds a significant position in the rabies prophylaxis market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market leadership. The primary risk lies in potential competition post-patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Rabies |
|---|---|
| Sponsor | Novartis Vaccines |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming. (PHASE3)
- A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody (PHASE2)
- R21/Matrix-M in African Children Against Clinical Malaria (PHASE3)
- Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine (PHASE3)
- Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults (PHASE3)
- Washington University WU 409: Immune Responses to Rabies Vaccine. (EARLY_PHASE1)
- Immunogenicity and Safety Assessment of Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rabies CI brief — competitive landscape report
- Rabies updates RSS · CI watch RSS
- Novartis Vaccines portfolio CI